shutterstock-191060012-web

Photo: Cvandyke / Shutterstock.com

7 May 2014Americas

FTC weighs in on “no-authorised-generic” antitrust case

The US Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case that concerns a “no-authorised-generic” settlement between Teva and GlaxoSmithKline (GSK).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

'This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Preventative IP for preventative pharma healthcare

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute